Final Results of a Phase 2 Multi‐Arm Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma

Documenti analoghi

• Phase 2 Multi‐Arm Study of Magrolimab Combinations in Patients With Acute Myeloid Leukaemia
  di: Gabriel N. Mannis, et al.
  Pubblicazione: (2025)
• Correction to “B‐cell Maturation Antigen‐Based Therapies Post‐Talquetamab in Relapsed or Refractory Multiple Myeloma”
  Pubblicazione: (2025)
• Early Free Light‐Chain Suppression as a Prognostic Marker in Relapsed and Refractory Myeloma Patients Treated With BCMA‐Directed CAR‐T Cells
  di: Tim Richardson, et al.
  Pubblicazione: (2025)
• Unheard Voices: Unmet Psychosocial Needs of Carers of Myeloma—A Service Evaluation Exploring Patient and Carer Perceived Benefits of Attending a Myeloma Support Group
  di: Kerrie Sweeney, et al.
  Pubblicazione: (2026)
• Teclistamab‐Induced Remission of Chronic Immune Thrombocytopenia in a Patient With Multiple Myeloma
  di: Renata Quevedo‐Salazar, et al.
  Pubblicazione: (2025)